Hire AI Developer for Biotech Startups
Senior, direct, no layers

The scarcest resource at a biotech startup is focused scientific time. Every hour a scientist spends reformatting data, chasing a CRO, or rebuilding an investor update is an hour not spent on the science the company exists to do.

An AI developer builds models that turn an operation's own records into decisions: which cases need attention first, where a bottleneck is forming, and what is likely to happen next. For biotech startups, that means models trained on the organization's own history, reviewed by staff, and never left to act alone on anything consequential.

Picture a CRO dataset arriving in a format nobody can use, days before an investor update is due. In that situation, a small model that ranks the queue by urgency and flags the cases most likely to stall would let staff act on the right cases first instead of working through the pile in arrival order. Book a free discovery call and we will test the fit on one real workflow before any wider scope is agreed.

The stack here is an electronic lab notebook such as Benchling, a LIMS, bioinformatics pipelines, and CRO data portals. The gap is usually connection, not tools: work lands in one system, records live in another, and nobody has one view of where a case stands. This engagement connects that stack and standardises the routines around it.

The model work starts from an electronic lab notebook such as Benchling and a LIMS, connecting to them rather than replacing tools the team already knows. Predictions are written back where staff already work, so nobody has to learn a new system to use the result.

This page describes services, not scientific or regulatory advice. Research and regulatory decisions stay with the startup's qualified scientific staff. FDA IND and BLA pathways shapes what can be automated or changed, and the work is scoped to fit it rather than work around it.

The realistic outcome is data the team can actually use: experiments findable, CRO results comparable, and updates assembled from real results instead of rebuilt each time.

Two problems deserve naming: experimental data scattered across notebooks and drives and CRO results arriving late or in unusable formats. Both persist when the underlying routine stays manual and nobody owns the follow-up, so each deliverable in this engagement is paired with a named owner and a visible queue, and problems surface while they are still small.

What changes is the order of work: the most urgent or most at-risk cases get attention first, and staff spend less time sorting and more time doing the work itself.

Browse all hire engagements or discuss your biotech startup workflow directly.